CM 9241 GRU
Alternative Names: CM-9241-GRULatest Information Update: 30 Sep 2024
At a glance
- Originator Ache Laboratories
- Class Antiallergics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Perennial allergic rhinitis
Most Recent Events
- 29 Aug 2024 Investigation in Perennial allergic rhinitis (unspecified route)
- 29 Aug 2024 Ache Laboratorios plans a phase III RESPIRE trial for Perennial allergic rhinitis in September 2024 (Unspecified, tablet) (NCT06577077)